{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:07:34Z","timestamp":1784038054888,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.urology.2026.05.012","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:41:42Z","timestamp":1779345702000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world Patterns of Genetic Testing in Urologic Malignancies: Guideline Recommendations Versus Clinical Practice"],"prefix":"10.1016","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5600-2001","authenticated-orcid":false,"given":"Sri Saran","family":"Manivasagam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay D.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2026.05.012_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32120698","article-title":"Precision care for hereditary urologic cancers: genetic testing, counseling, surveillance, and therapeutic implications","volume":"32","author":"Somoto","year":"2025","journal-title":"Curr Oncol"},{"key":"10.1016\/j.urology.2026.05.012_bib2","article-title":"Inherited germline variants in urinary tract cancer: a multicenter whole-exome sequencing analysis and correlation with clinical features and tumor genomics","volume":"8","author":"Kohlmann","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urology.2026.05.012_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2026.05.012_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2025.103804","article-title":"Expanding PARP inhibitor use in prostate cancer beyond DNA repair defects","volume":"44","author":"Palma Dos Reis","year":"2025","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.urology.2026.05.012_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.eururo.2024.09.003","article-title":"Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer and BRCA1\/2 gene alterations: final analysis from the randomized phase 3 MAGNITUDE trial","volume":"88","author":"Rathkopf","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.05.012_bib6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urology.2026.05.012_bib7","article-title":"Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis","volume":"3","author":"Chandran","year":"2024","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.urology.2026.05.012_bib8","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s00432-020-03251-5","article-title":"Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial","volume":"146","author":"Chen","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.urology.2026.05.012_bib9","doi-asserted-by":"crossref","first-page":"663 e611","DOI":"10.1016\/j.urolonc.2025.06.009","article-title":"Utilization of genetic evaluation in patients with kidney cancer who meet guidelines for genetic referral","volume":"43","author":"Makarova","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2026.05.012_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JU.0000000000001911","article-title":"Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA Guideline: Part I","volume":"206","author":"Campbell","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.05.012_bib11","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines(R) Insights: Bladder Cancer, Version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2026.05.012_bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines(R) Insights: Bladder Cancer, Version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2026.05.012_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2026.05.012_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2026.05.012_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN Guidelines(R) Insights: Kidney Cancer, Version 2.2024","volume":"22","author":"Motzer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2026.05.012_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2026.05.012_bib17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines(R) Insights: Prostate Cancer, Version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2026.05.012_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.6004\/jnccn.2022.7257","article-title":"Nationwide trends and determinants of germline BRCA1\/2 testing in patients with breast and ovarian cancer","volume":"21","author":"Lau-Min","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2026.05.012_bib19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/cge.14100","article-title":"Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large US health care system","volume":"101","author":"Powell","year":"2022","journal-title":"Clin Genet"},{"key":"10.1016\/j.urology.2026.05.012_bib20","unstructured":"NCCN Guidelines Neuroendocrine and Adrenal Tumors Version 3.2025, \u3008https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1448\u3009 (2025)."},{"key":"10.1016\/j.urology.2026.05.012_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update","volume":"79","author":"Roupret","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.05.012_bib22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2026.05.012_bib23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2024.0851","article-title":"Genetic testing in men with metastatic castration-resistant prostate cancer","volume":"10","author":"Barata","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2026.05.012_bib24","article-title":"Genetic testing among black and white patients with advanced prostate cancer: a retrospective analysis of testing utilization and referral patterns","volume":"20251207","author":"McElyea","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2026.05.012_bib25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/jgc4.1786","article-title":"Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer","volume":"33","author":"Bergerot","year":"2024","journal-title":"J Genet Couns"},{"key":"10.1016\/j.urology.2026.05.012_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2023.107539","article-title":"Racial disparities in cascade testing for cancer predisposition genes","volume":"172","author":"Kassem","year":"2023","journal-title":"Prev Med"},{"key":"10.1016\/j.urology.2026.05.012_bib27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.euo.2023.07.008","article-title":"Efficacy of national comprehensive cancer network guidelines in identifying pathogenic germline variants among unselected patients with prostate cancer: the PROCLAIM trial","volume":"6","author":"Shore","year":"2023","journal-title":"Eur Urol Oncol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526003183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526003183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:41:47Z","timestamp":1784036507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429526003183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"alternative-id":["S0090429526003183"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2026.05.012","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Patterns of Genetic Testing in Urologic Malignancies: Guideline Recommendations Versus Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2026.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}